Targeting cancer complexity at origin and progression
Our research is focused on better understanding breast cancer initiation and, from acquired knowledge, to assess targeted prevention strategies. In parallel, we study pan-cancer vulnerabilities and the connection to a rare, lung metastatic disease, lymphangioleiomyomatosis (LAM).
Group members
Principal investigator
Research assistant
PhD student
PhD student
PhD student
PhD student
Publications
Genome Med. 2024 Feb 2;16(1):21. doi: 10.1186/s13073-024-01294-8. ABSTRACT BACKGROUND: The immune system has a central role in preventing carcinogenesis. Alteration of systemic immune cell levels may increase cancer risk. However, the extent to which common genetic variation influences blood traits and cancer risk remains largely undetermined. Here, we identify pleiotropic variants and predict their underlying […]
Cancer Res. 2023 Nov 21:OF1-OF15. doi: 10.1158/0008-5472.CAN-22-2948. Online ahead of print. ABSTRACT MYC is a central regulator of gene transcription and is frequently dysregulated in human cancers. As targeting MYC directly is challenging, an alternative strategy is to identify specific proteins or processes required for MYC to function as a potent cancer driver that can […]
Cell Rep. 2023 Oct 25;42(11):113382. doi: 10.1016/j.celrep.2023.113382. Online ahead of print. NO ABSTRACT PMID:37883228 | DOI:10.1016/j.celrep.2023.113382
Cell Rep. 2023 Oct 31;42(10):113256. doi: 10.1016/j.celrep.2023.113256. Epub 2023 Oct 16. ABSTRACT It is widely assumed that all normal somatic cells can equally perform homologous recombination (HR) and non-homologous end joining in the DNA damage response (DDR). Here, we show that the DDR in normal mammary gland inherently depends on the epithelial cell lineage identity. […]
Nucleic Acids Res. 2023 Oct 27;51(19):10484-10505. doi: 10.1093/nar/gkad733. ABSTRACT Breast cancer linked with BRCA1/2 mutations commonly recur and resist current therapies, including PARP inhibitors. Given the lack of effective targeted therapies for BRCA1-mutant cancers, we sought to identify novel targets to selectively kill these cancers. Here, we report that loss of RNF8 significantly protects Brca1-mutant […]
Research Projects
The group works and collaborates to decipher the systems mechanisms of cancer development and progression, with the aim of developing more precise preventive and therapeutic approaches. The group combines in silico and wet-lab studies for the purpose of identifying cancer principles and vulnerabilities.
Collaborations
CIMBA – Consortium of Investigators of Modifiers of BRCA1/2
https://cimba.ccge.medschl.cam.ac.uk/
Lobular Breast Cancer
https://lobsterpot.eu/
BRCA1 breast cancer
Khokha Lab
https://medbio.utoronto.ca/faculty/khokha
Hakem Lab
https://medbio.utoronto.ca/faculty/hakem
Maxwell Lab
https://www.bcchr.ca/cmaxwell
Serra Lab
https://vhio.net/biosketch-violeta-serra/
Cancer biology
Schramek Lab
https://schramek.lunenfeld.ca/
Li Lab
https://lilab.smhs.gwu.edu/
Barcellos-Hoff Lab
https://barcelloshofflab.ucsf.edu/principal-investigator
Cancer genetics
De Cid Lab – GCAT
http://www.gcatbiobank.org/
LAM research
Johnson Lab – LAM UK
https://www.nottingham.ac.uk/medicine/people/simon.johnson
Elżbieta Radzikowska
National Tuberculosis and Lung Diseases Research Institute, Poland
Kwiatkowski Lab
https://www.kwiatkowskilab.org/
AELAM
https://www.aelam.org/
VHIR
https://vhir.vallhebron.com/en/research/pneumology
Molina Lab
https://idibell.cat/en/research/translational-medicine-area/cardiovascular-respiratory-and-systemic-diseases-and-cellular-aging-program/pneumology/
Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952
Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069
Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087
Menendez’s Lab